Akums, Microcore Research enter JV to develop NESM dietary supplements

By: India Pharma Outlook Team | Monday, 31 October 2022

 India Pharma Outlook Team
Akums Drugs & Pharmaceuticals Ltd has entered into a joint venture with Microcore Research. With this tie-up, Akums will now leverage natural eggshell membrane (NESM) and develop dietary supplements for maintaining healthy joint and connective tissues.

NESM is a novel dietary supplement that contains naturally occurring glycosaminoglycans and proteins essential for maintaining healthy joint and connective tissues. Its natural composition is a very interesting product to use as a natural source of collagen, elastin, hyaluronic acid, chondroitin sulphate and other key biomolecules.

Several scientific studies have shown the great effectiveness of the eggshell membrane as an ingredient for food supplements, in such diverse areas as bones, tendons and joint health, skin, hair and nails and several others. NESM is organically derived from poultry eggs, it naturally contains glucosamine & chondroitin that supports healthy joints. It is an effective and safe option for the treatment of pain and stiffness associated with knee osteoarthritis.

Sanjeev Jain, Founder, Promoter and Director, Akums Drugs & Pharmaceuticals, said, “Poor bone and joint health is gradually becoming a serious public health concern. The World Health Organisation (WHO) has kept osteoporosis second (with cardiovascular diseases at the top) on the list of serious global healthcare problems. About one in three women over 30 years of age experience fractures related to osteoporosis. Despite the widespread prevalence, it is an under-recognised public health concern that needs immediate attention. The lack of knowledge and awareness about this crippling disease has translated into a significant human and economic burden on India. Improper dietary habits and an increasingly indoor lifestyle are now putting the relatively younger generation at risk.”

In the same vein Sandeep Jain, Founder, Promoter and Director, Akums Drugs & Pharmaceuticals commented, “In osteoporosis patients, the rate at which new bone cells are formed is much lower than the rate of resorption or dissolution of the bone matrix. Low bone density makes bones prone to fractures, the most common ones being those of the hip, and peripheral joints such as wrists and spine. To bridge the existing gap, we tied up with them and we are happy to announce that we will be the sole seller of innovative NESM supplements to the Indian market.”

Akums has also received 1st-time FSSAI approval for the molecule in India with a health claim.

© 2022 India Pharma Outlook. All Rights Reserved.